# Iovance Biotherapeutics Inc. (IOVA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.79, market value $4.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Iovance Biotherapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 12.3×**. Each dollar of revenue is priced at 12.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.4×**. The shares trade at 5.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -7.4%** (5-yr avg -22.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -92.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -148.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -56.0%**. Return on equity is negative because earnings are negative.
- **Return on assets: -31.7%**. Each dollar of assets produces -31.7% of profit.

## Growth
- **Revenue growth (1 yr): 60.6%**. Revenue grew 60.6% over the last year.
- **EPS growth (1 yr): 14.8%**. Earnings per share rose 14.8%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 3.20** (quick 3.20). Current assets cover the next year's liabilities 3.20 times.
- **Altman Z-score: 11.43**. A Z-score of 11.43 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Iovance Biotherapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover Iovance Biotherapeutics Inc.; the consensus is buy, with an average price target of $10.00 (+14% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 299.5%** (YTD 222.0%, 3-mo 107.8%). The shares are up 299.5% over twelve months including dividends.
- **From 52-week high: -6.1%** (399.4% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 70**. An RSI of 70 is neutral.
- **Beta (1 yr): 1.29** (volatility 101%). Beta of 1.29 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IOVA · Page: https://foliofundamentals.com/stocks/iova

Not investment advice.